» Articles » PMID: 25435936

Craniopharyngioma: Survivin Expression and Ultrastructure

Overview
Journal Oncol Lett
Specialty Oncology
Date 2014 Dec 2
PMID 25435936
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to investigate the significance of survivin protein expression levels in craniopharyngioma. Tumor samples and clinical data were obtained from 50 patients with craniopharyngioma who were admitted to the West China Hospital of Sichuan University (Chengdu, China). The morphology of the craniopharyngioma samples was observed using optical and electron microscopes, and survivin expression was investigated in the samples by immunohistochemical analysis. The immunohistochemical results revealed survivin expression in all of the craniopharyngioma samples, but not in the healthy brain tissue samples. It was identified that survivin was expressed at a higher level in cases of the adamantinomatous type compared with those of the squamous-papillary type, in male patients compared with female patients, in children compared with adults and in recurrent cases compared with non-recurrent cases. Furthermore, no significant difference was detected in survivin expression levels among the tumors of different subtypes and different disease stages. The results of the present study indicate that survivin is significant in the development of craniopharyngioma, and that survivin protein expression levels are a meaningful indicator for assessing craniopharyngioma recurrence.

Citing Articles

Integrin 6 Indicates a Poor Prognosis of Craniopharyngioma through Bioinformatic Analysis and Experimental Validation.

Jia Y, Wu W, Xiao Y, Cai K, Gui S, Li Q J Oncol. 2022; 2022:6891655.

PMID: 36268277 PMC: 9578790. DOI: 10.1155/2022/6891655.


Treatment of Cystic Craniopharyngiomas: An Update.

Bianchi F, Benato A, Massimi L Adv Tech Stand Neurosurg. 2022; 45:139-176.

PMID: 35976449 DOI: 10.1007/978-3-030-99166-1_4.


Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Coury J, Davis B, Koumas C, Manzano G, Dehdashti A Neurosurg Rev. 2018; 43(1):41-48.

PMID: 29666970 DOI: 10.1007/s10143-018-0978-5.


Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.

Gonzalez-Meljem J, Haston S, Carreno G, Apps J, Pozzi S, Stache C Nat Commun. 2017; 8(1):1819.

PMID: 29180744 PMC: 5703905. DOI: 10.1038/s41467-017-01992-5.

References
1.
Carmel P, Antunes J, Chang C . Craniopharyngiomas in children. Neurosurgery. 1982; 11(3):382-9. DOI: 10.1227/00006123-198209000-00008. View

2.
Kawano N, Oka H, Suwa T, Ito H, Yada K, Kameya T . Origin of craniopharyngioma: an electron microscopic study. Noshuyo Byori. 1993; 10(2):117-23. View

3.
Rath S, Lee S, Kotecha R, Taylor M, Junckerstorff R, Choong C . Childhood craniopharyngioma: 20-year institutional experience in Western Australia. J Paediatr Child Health. 2013; 49(5):403-8. DOI: 10.1111/jpc.12190. View

4.
Tena-Suck M, Hernandez-Campos M, Ortiz-Plata A, Salinas-Lara C, Colin-Gonzalez A, Santamaria A . Intracerebral injection of oil cyst content of human craniopharyngioma (oil machinery fluid) as a toxic model in the rat brain. Acta Histochem. 2013; 116(3):448-56. DOI: 10.1016/j.acthis.2013.10.002. View

5.
Ujifuku K, Matsuo T, Takeshita T, Hayashi Y, Hayashi K, Kitagawa N . Malignant transformation of craniopharyngioma associated with moyamoya syndrome. Neurol Med Chir (Tokyo). 2010; 50(7):599-603. DOI: 10.2176/nmc.50.599. View